2,6 SUSTITUIDO-4-MONOSUSTITUIDO AMINO-PIRIMIDINAS COMO ANTAGONISTAS DEL REPECTOR DE PROSTAGLANDINA D2

• Main Authors: GARNER CHARLES J, LIM SUNGTAEK, STEFANY DAVID, HARRIS KEITH JOHN, AGUIAR JOACY C, DECHAUX ELSA A, CAO BIN, HUNT HAZEL J, BOFFEY RAY, GILLESPY TIMOTHY A
• Format: Patent
• Language: Spanish
• Published: 04.10.2007
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; METALLURGY; ORGANIC CHEMISTRY

La presente invencion se refiere a un compuesto de Formula (I) en la que Cy1, Cy2, L1, L2 y R1 son como se definen en este documento, a una composicion farmaceutica que comprende una cantidad farmaceuticamente eficaz de uno o mas compuestos de acuerdo con la Formula (I) en mezcla con un vehiculo farmaceuticamente aceptable, a un metodo para tratar a un paciente que padece un trastorno mediado por la PGD2 incluyendo, pero sin limitacion, asma bronquial, enfermedad pulmonar obstructiva cronica (COPD), rinitis alergica, dermatitis alergica, conjuntivitis alergica, bronquitis, mastocitosis sistemica y lesion de reperfusion isquemica por medio de la administracion a dicho paciente de una cantidad farmaceuticamente eficaz de un compuesto de acuerdo con la Formula (I). The present invention is directed to a compound of Formula (I) wherein Cy1, Cy2, L1, L2, and R1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).